Rocatinlimab for treating moderate to severe atopic dermatitis in people 12 years and over [ID6565]

  • Awaiting development
  • GID-TA11759
  • Expected publication date: TBC
To appraise the clinical and cost effectiveness of Rocatinlimab within its marketing authorisation for treating dermatitis ID6565